A retrospective study showed that patients treated with GLP-1 receptor agonists (GLP-1 RA) to control diabetes had a significantly lower risk of developing colorectal cancer (CRC) compared to those taking aspirin.[1] The probability of developing colon cancer was 44% lower in patients on GLP-1 RA during the study period.[1] The study was conducted in San Francisco and analyzed patients with a history of such treatment.[1] GLP-1 agonists, such as semaglutide (Ozempic, Wegovy) or tirzepatid, were originally intended for the treatment of type 2 diabetes.[3] These drugs reduce the risk of several obesity-related cancers, including colon cancer, by up to 50%.[3] The reduction in risk was directly proportional to weight loss.[3] The studies followed hundreds of thousands of patients over a long period of time and were published in The Lancet and The New England Journal of Medicine.[3]